Vasomedical Inc (VASO) 0.2200 $VASO
Vasomedical Receives Approvals to Market Its Products in Brazil
ACCESSWIRE - Tue Sep 02, 8:04AM CDT
Vasomedical to Market and Sell EECP Therapy, BIOX ECG Holter and Ambulatory Blood Pressure Monitoring Products in Brazil
Vasomedical Announces Second Quarter 2014 Results
Marketwire - Wed Aug 13, 8:01AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTCBB: VASO) today reported its operating results for the three months ended June 30, 2014.
Vasomedical to Report Second Quarter 2014 Results on August 13, 2014
ACCESSWIRE - Wed Aug 06, 8:18AM CDT
Management to hold investor conference call on August 13th at 10:00 a.m. ET
Vasomedical Signs Agreement with GE Healthcare IT to Become National Value Added Reseller for Radiology PACS Software Solutions
PR Newswire - Wed Jul 16, 8:00AM CDT
Vasomedical, Inc. ("Vasomedical" ("the Company" (OTC BB: VASO) today announced the signing on June 27, 2014 of a Value Added Reseller Agreement ("VAR Agreement" with GE Healthcare ("GEHC" , a division of General Electric Company (NYSE: GE), to become a national value added reseller for GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by VasoHealthcare, a wholly owned subsidiary of Vasomedical, on behalf of GE Healthcare and is effective immediately.
Vasomedical posts lesser net loss of USD1.1m and revenue growth of 12% in 2013
M2 - Fri Mar 28, 7:31AM CDT
Medical technology company Vasomedical (OTC BB:VASO) stated on Thursday its net loss of USD1.1m (USD0.01 per common share) for the year ended 31 December 2013.
Citigroup Shares Drop After Failing Fed Stress Test; Applied Genetic Technologies Announces IPO
ACCESSWIRE - Thu Mar 27, 11:38PM CDT
Citigroup Inc. (NYSE: C) - For an in-depth report on Citigroup Inc. follow: www.BullTrends.com/stockquote/C
Vasomedical Announces Financial Results for Fourth Quarter and Full Year for 2013
PR Newswire - Thu Mar 27, 8:15AM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO) today reported its operating results for the three months and year ended December 31, 2013.
Vasomedical to Report Fourth Quarter and Year End 2013 Results on March 27, 2014
PR Newswire - Fri Mar 21, 7:00AM CDT
Vasomedical, Inc. (OTC BB: VASO) announced today that it will release its financial results for the three months ended and year ended December 31, 2013 on Thursday, March 27, 2014.
Vasomedical Announces Biox's MobiCare(TM) Wireless Patient Monitors Receives Marketing Approval in China
PR Newswire - Mon Mar 17, 7:00AM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that its wholly owned subsidiary Biox Instruments Co. Ltd., based in Wuxi, China, has received approval from the Chinese Food and Drug Administration (CFDA) to begin marketing its new MobiCare Wireless Patient Monitors in China.
Newfield Exploration Closes On Sale Of Its Malaysian Business
PR Newswire - Tue Feb 11, 7:00AM CST
Newfield Exploration Company (NYSE: NFX) today announces the closing of the previously announced sale of its business offshore Malaysia to SapuraKencana Petroleum Berhad, receiving total proceeds of approximately $898 million. The Share Purchase Agreement was originally executed with SapuraKencana on October 22, 2013, with an effective date of June 30, 2013. Proceeds from the sale will be used to reduce short-term borrowings under Newfield's credit facility and for general corporate purposes.
FDA Reclassifies ECP Devices for Refractory Angina as Class II
PR Newswire - Mon Jan 06, 3:25PM CST
Vasomedical, Inc. ("Vasomedical" (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that the U.S. Food and Drug Administration (FDA), Department of Health and Human Services, issued its final order on December 30, 2013, reclassifying external counter-pulsating (ECP) devices for treatment of chronic stable angina for patients that are refractory to anti-anginal medical therapy and without options for revascularization from class III to class II (special controls).
EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
PR Newswire - Mon Sep 09, 7:30AM CDT
Vasomedical, Inc. ("Vasomedical" (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that its EECP Therapy has been given a lla Class of Recommendation in the 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD). The guidelines were released during ESC's annual meeting which took place from August 31 to September 3, 2013 in Amsterdam, the Netherlands.
OTC Daily Alert Stock Watch - Vasomedical, Inc. (OTCQB: VASO)
WorldStockWire - Fri Sep 06, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Vasomedical Announces Financial Results for the Second Quarter of 2013
PR Newswire - Tue Aug 13, 3:05PM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO) today reported its operating results for the three months ended June 30, 2013.
Vasomedical Inc is Featured as the Daily Momentum Gainer to watch on Smallcappower.com
Newsfile Corp - Fri Aug 09, 9:37AM CDT
full story)
Vasomedical to Raise Awareness about EECP® Therapy as an Effective Treatment for Heart Disease in Diabetic Patients
PR Newswire - Mon Jun 03, 7:30AM CDT
The American Heart Association (AHA) Heart Disease and Stroke 2013 Statistical Update reported that 19.7 million Americans over the age of twenty have physician-diagnosed diabetes, and there are an additional eight million Americans with undiagnosed diabetes. The top causes of disability and death among patients with diabetes are heart disease and stroke, and these patients suffer more complications and higher failure rate with the current methods of treating heart disease, including medication, stenting and bypass surgery. It has been long established that Enhanced External Counterpulsation (EECP®) Therapy, a noninvasive treatment for patients with ischemic heart disease, is equally effective in treating heart disease for diabetic patients as it is in the non-diabetic patient population.
Vasomedical Announces Financial Results for the First Quarter of 2013
PR Newswire - Wed May 15, 3:15PM CDT
Vasomedical, Inc. ("Vasomedical" (OTC BB: VASO) today reported its operating results for the three months ended March 31, 2013.
Vasomedical to Report First Quarter 2013 Results on May 15, 2013
PR Newswire - Wed May 08, 8:00AM CDT
Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended March 31, 2013 on Wednesday, May 15, 2013.
Randy Hill Appointed to Vasomedical Board of Directors
PR Newswire - Wed Apr 17, 8:00AM CDT
Vasomedical, Inc. (OTC BB: VASO) (the "Company" , a diversified medical technology company specializing in the design, manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, today announced the appointment of Mr. Randy Hill to the Board of Directors effective immediately.
Vasomedical Receives Approvals to Market Its Products in Brazil
ACCESSWIRE - Tue Sep 02, 8:04AM CDT
Vasomedical to Market and Sell EECP Therapy, BIOX ECG Holter and Ambulatory Blood Pressure Monitoring Products in Brazil
Vasomedical Announces Second Quarter 2014 Results
Marketwire - Wed Aug 13, 8:01AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTCBB: VASO) today reported its operating results for the three months ended June 30, 2014. Vasomedical to Report Second Quarter 2014 Results on August 13, 2014
ACCESSWIRE - Wed Aug 06, 8:18AM CDT
Management to hold investor conference call on August 13th at 10:00 a.m. ET
Vasomedical Signs Agreement with GE Healthcare IT to Become National Value Added Reseller for Radiology PACS Software Solutions
PR Newswire - Wed Jul 16, 8:00AM CDT
Vasomedical, Inc. ("Vasomedical"
("the Company" (OTC BB: VASO) today announced the signing on June 27, 2014 of a Value Added Reseller Agreement ("VAR Agreement" with GE Healthcare ("GEHC" , a division of General Electric Company (NYSE: GE), to become a national value added reseller for GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by VasoHealthcare, a wholly owned subsidiary of Vasomedical, on behalf of GE Healthcare and is effective immediately. Vasomedical posts lesser net loss of USD1.1m and revenue growth of 12% in 2013
M2 - Fri Mar 28, 7:31AM CDT
Medical technology company Vasomedical (OTC BB:VASO) stated on Thursday its net loss of USD1.1m (USD0.01 per common share) for the year ended 31 December 2013.
Citigroup Shares Drop After Failing Fed Stress Test; Applied Genetic Technologies Announces IPO
ACCESSWIRE - Thu Mar 27, 11:38PM CDT
Citigroup Inc. (NYSE: C) - For an in-depth report on Citigroup Inc. follow: www.BullTrends.com/stockquote/C
Vasomedical Announces Financial Results for Fourth Quarter and Full Year for 2013
PR Newswire - Thu Mar 27, 8:15AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO) today reported its operating results for the three months and year ended December 31, 2013. Vasomedical to Report Fourth Quarter and Year End 2013 Results on March 27, 2014
PR Newswire - Fri Mar 21, 7:00AM CDT
Vasomedical, Inc. (OTC BB: VASO) announced today that it will release its financial results for the three months ended and year ended December 31, 2013 on Thursday, March 27, 2014.
Vasomedical Announces Biox's MobiCare(TM) Wireless Patient Monitors Receives Marketing Approval in China
PR Newswire - Mon Mar 17, 7:00AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that its wholly owned subsidiary Biox Instruments Co. Ltd., based in Wuxi, China, has received approval from the Chinese Food and Drug Administration (CFDA) to begin marketing its new MobiCare Wireless Patient Monitors in China. Newfield Exploration Closes On Sale Of Its Malaysian Business
PR Newswire - Tue Feb 11, 7:00AM CST
Newfield Exploration Company (NYSE: NFX) today announces the closing of the previously announced sale of its business offshore Malaysia to SapuraKencana Petroleum Berhad, receiving total proceeds of approximately $898 million. The Share Purchase Agreement was originally executed with SapuraKencana on October 22, 2013, with an effective date of June 30, 2013. Proceeds from the sale will be used to reduce short-term borrowings under Newfield's credit facility and for general corporate purposes.
FDA Reclassifies ECP Devices for Refractory Angina as Class II
PR Newswire - Mon Jan 06, 3:25PM CST
Vasomedical, Inc. ("Vasomedical"
(OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that the U.S. Food and Drug Administration (FDA), Department of Health and Human Services, issued its final order on December 30, 2013, reclassifying external counter-pulsating (ECP) devices for treatment of chronic stable angina for patients that are refractory to anti-anginal medical therapy and without options for revascularization from class III to class II (special controls). EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
PR Newswire - Mon Sep 09, 7:30AM CDT
Vasomedical, Inc. ("Vasomedical"
(OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that its EECP Therapy has been given a lla Class of Recommendation in the 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD). The guidelines were released during ESC's annual meeting which took place from August 31 to September 3, 2013 in Amsterdam, the Netherlands. OTC Daily Alert Stock Watch - Vasomedical, Inc. (OTCQB: VASO)
WorldStockWire - Fri Sep 06, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Vasomedical Announces Financial Results for the Second Quarter of 2013
PR Newswire - Tue Aug 13, 3:05PM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO) today reported its operating results for the three months ended June 30, 2013. Vasomedical Inc is Featured as the Daily Momentum Gainer to watch on Smallcappower.com
Newsfile Corp - Fri Aug 09, 9:37AM CDT
full story)
Vasomedical to Raise Awareness about EECP® Therapy as an Effective Treatment for Heart Disease in Diabetic Patients
PR Newswire - Mon Jun 03, 7:30AM CDT
The American Heart Association (AHA) Heart Disease and Stroke 2013 Statistical Update reported that 19.7 million Americans over the age of twenty have physician-diagnosed diabetes, and there are an additional eight million Americans with undiagnosed diabetes. The top causes of disability and death among patients with diabetes are heart disease and stroke, and these patients suffer more complications and higher failure rate with the current methods of treating heart disease, including medication, stenting and bypass surgery. It has been long established that Enhanced External Counterpulsation (EECP®) Therapy, a noninvasive treatment for patients with ischemic heart disease, is equally effective in treating heart disease for diabetic patients as it is in the non-diabetic patient population.
Vasomedical Announces Financial Results for the First Quarter of 2013
PR Newswire - Wed May 15, 3:15PM CDT
Vasomedical, Inc. ("Vasomedical"
(OTC BB: VASO) today reported its operating results for the three months ended March 31, 2013. Vasomedical to Report First Quarter 2013 Results on May 15, 2013
PR Newswire - Wed May 08, 8:00AM CDT
Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months ended March 31, 2013 on Wednesday, May 15, 2013.
Randy Hill Appointed to Vasomedical Board of Directors
PR Newswire - Wed Apr 17, 8:00AM CDT
Vasomedical, Inc. (OTC BB: VASO) (the "Company"
, a diversified medical technology company specializing in the design, manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, today announced the appointment of Mr. Randy Hill to the Board of Directors effective immediately. 
